Wedbush Reiterates “Outperform” Rating for Obseva (NASDAQ:OBSV)

Wedbush reaffirmed their outperform rating on shares of Obseva (NASDAQ:OBSV) in a research note published on Thursday morning, RTT News reports. They currently have a $38.00 price objective on the stock.

Several other research firms have also recently weighed in on OBSV. HC Wainwright reissued a buy rating on shares of Zomedica Pharmaceuticals in a research report on Wednesday, June 5th. Zacks Investment Research raised York Water from a sell rating to a hold rating in a research report on Saturday, June 1st. Finally, ValuEngine cut Valero Energy from a hold rating to a sell rating in a research report on Wednesday, May 8th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Obseva has an average rating of Buy and a consensus target price of $29.80.

OBSV stock opened at $10.05 on Thursday. The stock has a fifty day simple moving average of $11.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.73 and a current ratio of 6.73. Obseva has a 1-year low of $9.19 and a 1-year high of $19.40. The stock has a market capitalization of $457.05 million, a PE ratio of -5.26 and a beta of 0.94.

Obseva (NASDAQ:OBSV) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. As a group, equities research analysts forecast that Obseva will post -2.32 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Fosun International Ltd purchased a new stake in Obseva during the 1st quarter worth about $2,494,000. Dimensional Fund Advisors LP lifted its holdings in Obseva by 274.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 70,573 shares of the company’s stock worth $893,000 after purchasing an additional 51,733 shares in the last quarter. Wedbush Securities Inc. lifted its holdings in Obseva by 86.1% during the 1st quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock worth $496,000 after purchasing an additional 17,950 shares in the last quarter. United Services Automobile Association lifted its holdings in Obseva by 132.3% during the 4th quarter. United Services Automobile Association now owns 26,480 shares of the company’s stock worth $335,000 after purchasing an additional 15,080 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC lifted its holdings in Obseva by 4.5% during the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 21,000 shares of the company’s stock worth $266,000 after purchasing an additional 905 shares in the last quarter. 63.58% of the stock is currently owned by institutional investors and hedge funds.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Read More: How to start trading in the forex market?

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.